Bamlanivimab received emergency use authorization (EUA) from the U.S. Food and Drug Administration on November 9, 2020... Nov 23
The independent, pre-programmed DSMB unanimously recommends the continuation of the global Phase 2/3 study of orally administered opaganib in severe COVID-19 pneumonia... Nov 23
The clinical evidence from Regeneron's outpatient trial suggests that monoclonal antibodies such as REGEN-COV2 have the greatest benefit when given early after diagnosis ... Nov 23
-Advertisements-